Enhancement of effector functions of anti-CD20 monoclonal antibody by increased afucosylation in CHO cell line through cell culture medium optimization

BACKGROUND: Recombinant therapeutic anti-CD20 monoclonal antibody (mAb) is used for the treatment of non-Hodgkin’s lymphoma, a common B cell lymphoma constituting 80% of all lymphomas. Anti-CD20 mAb contains an Fc-linked biantennary glycan. Although, anti-CD20 monoclonal antibodies are being increas...

Descripción completa

Detalles Bibliográficos
Autores principales: Bheemareddy, Bala Reddy, Reddy, Prakash Narayana, Vemparala, Kranthi, Dirisala, Vijaya R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532503/
https://www.ncbi.nlm.nih.gov/pubmed/36194313
http://dx.doi.org/10.1186/s43141-022-00421-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532503/
https://www.ncbi.nlm.nih.gov/pubmed/36194313
http://dx.doi.org/10.1186/s43141-022-00421-5

Ejemplares similares